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Avoiding Interpretive Pitfalls When Assessing Arrhythmia Suppression
After Myocardial Infarction : Insights From the Long-Term
Observations of the Placebo-Treated Patients in the Cardiac
Arrhythmia Pilot Study (CAPS)
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The Cardiac Arrhythmia Pilot Study CAPE was a I sear trial
That analyzed the safety and effectiveness of arrhythmia suppens
•
sion in 502 patients surviving acute myocardial inrarelion ra -ho hod
?10 ventricular premature depotarizatinasih or
:_
: runs of --
tricolor tachycIndia om a Holler re-ding obtained 6 to 60 days
after the acute infarction. Because 1011 of these paucity received
placebo in a double-blind fashion for ? year . a eomprehensise
objective analysis was performed of spontaneous arrhythmia
changes
based on real data rather than statistical eslimates .
In the CAN placebo group. 19% developed some serious
clinical event in 1 year Ideath
. heart failure. peoarrhylhmiat that
could likely be attributable to aeliarrhythmic drst mvicity, %
significant reduction in the frequency of sentricular premature
depolarizatioas Ip = 0.0041 occurred in the hot fee, weeks of
"therapy" snithafurthersignifirantIp 0 .INIdecreasehetneon
3 to 12 months- Stirs initiation of placebo entiarrhvthmiv ther-
Ventricular premature depalarimliun, predict murt,ht}' fit-
ter acute myocardial infarction 11-41 . Several trials 0 .41
have utilised amhuiatory cleetricardiucraphic iFC(i) re-
cordings IHolter recurdinc,l to ostehlhh that ventricular
prcntnture depolariaatiuns arc es,weialed ,sith an increased
risk of sudden cardiac death independent of the effect ofIct'i
ventricular function . Despite conclusive etidence demon.
straliny nn association h'l ueen ventricular arrhvthmias and
prttnosis after acute myocardial i nfarction . n o evidence
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, l*)I h, the :\macro ( nllcuc nl t' .ududop,
upy, 17°1 had "dppareni sentritular premature depalariralion
aippreseind • I ,70'r reductium after ran Holler renirdiog esal-
ration and nearly half 11BR 1 after sir Hotter recordings to assess
mpprvcsinn mere performed .
It is cmrcluded That I I selling a higher percent suppression goal
or nhtainina multiple baseline Holler recordings decreases the
chance al mistaking suppression for spontaneous variability :
2?
chaining
frequent individual Holler recordings over the course
of drug they=_p, achiatly inerrases the chance of sampling during
one estrunte,ariahilite period. Ihereseelt of which is to incorrectly
infer "sopprecsiun" or "proarrhytbmia" : and 3) runs of ventric.
ular taehscarihamar In the CAPS study group infrequently, are
of Ion density and exhibit estreme variability such that a primary
suppression goal focused on runs of ventricular tachycardia is not
a reliable nod point for assessing aotiarrby7hmie therapy
.
IJ 'im Coll Cordial 199187 ;1-8r
011I,lo cupporl a slratdgv that suppressing these centricu-
Iar
premature
depolarications would faserobl alter clinical
outcome . [he recent disclosure 15) from the Cardiac .Ar-
rh}thmia Suppression Trial ICASI) documented an ecces-
,ive mortJhn rate with tlecninide and encninide therapy
despite arrhythmia suppression in patients with ventricular
arrhythmia surviving myocardial infarction . The Cardiac
Arrhythmia Pilot Study ICAPSI
.
from nthich the full-scale
study i riginalad . teas designed to obtain knowledge used to
implement CAST (6,7) .
the assessment of the evtent of J«hythma suppression is
usua
.llt uv,luated using Halter recordings before and after
initiation of therapy- Such an approach was used in CAST
dl . PrecIOU' 'cludi .
.I5-141 have shown that the frequencv
of Aennicular arrhrthmias varies markedly over the curly
recotery
,
pet ot'. after acute mr'ccnidial infarction. mole
Intcstlguwh 1131 have
suggested
that arrhythmia prevalence
after min' ardiai infarction is increased after hospital dis-
charge compared with before dischar0u, In addition to these
reported long-term changes in the prevalence of ventricular
arrhythmia- a'tcr acute myocardial infarction
. a number of
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invesli€ators 0 ;_20 have documented a large individual
variability in laity vemricular premature depotarixution ant,
nonsustained ventricular tachycardia frequency both in pa-
tients with various cardiac disorders I I S_I9t and inpatients
surviving acute myocardial infarction €_'01 . These changes
confound the clinicians attempt to accurately assess ar-
rhythmia suppression by antiarrhythmic drugs .
Based on these observations, using the statistical ap-
proach of analysis of variance . investigators tl7-2ol have
created tables establishing confidence limits fur interpreting
the ektent of arrhythmia suppression as judged by Holier
recording . These tables provide clinicians with information
on the degree of short-term ventricular arrhythmia suppres-
sion that can he attributed to an antiarrhythmic drug effect .
Suppression of ventricular premature depo[arizations in
most groups of patients must exceed 70% to tt0!i of the
baseline value when based on one 24-h Holier recording
before and one recording after initiation of antiarrhythmic
therapy 117,191- However. ventricular premature depolarize.
lion variability may be greater in patients with coronary
heart disease . especially in patients recovering Gum recent
myocardial infarction (19
.201. '1 be malor limitation of these
past observations of arrhythmia variability is the short
duration over which the data were collected based on only
to S consecutive days of Holier recordings during placebo
therapy 117-201_ Of greater importance is the fact that these
data are statistical estimates that do not include actual
long-term patient data.
1n contrast . CAPS followed up 502 patierds with an
average of eight Holier recordings over a period of 12
months, Four suppression therapies were assessed and
compared with a parallel double-ulind placebo-treated group
In = 1001
. This study focuses on an analysis of the arrhyth-
mia changes in the placebo group, which provides a unique
opportunity to study the long-term natural history and vari-
ability of postinfarclien ventricular arrhythmia.. including
potential clinical implications for more precise arrhythmia
management- Knowledge or the long-term natural variation
of these arrhythmias should result in a more thoughtful use
of antiarrhythmic drugs, which have well-documented tox-
icity and proarrhy[hmic effects 15.21-24) . Thus. in [his
As.' Vul. I'. No . I
Jame~rp 19 V1 1-a
FiNae I • DLSSing ,equ,r,e in the Cardiac Arrhyth-
mia Pilot Study ICAPSI. In the placebo group .
during Hotter recordings were obtained until appar-
ent elhicacs suppression was achieved . Suppres-
sion v:
as judged by comp"nsoo with baseline . suc-
cess - -70`". 'nutncular premature depolaricalico
partial meeess - sir, hot .Ti(l rd".
IiM! : falure = <
50%
reduction teen S1cttodslr
study . we analyzed and characterized the magnitude and
rs
.aien-<of long-term changes in ventricular premature
depolarizalions and runs of ventricular tachycardia in the
100 CAPS patients taking placebo tablets during a I year
double-blind study .
' o... Dose
Study Design
Study patients
. The design and results of CAPS are
detailed elsewhere I6.7) . thus
. only a brief review of aspects
relevant to this study is presented here, All patients entered
into CAPS gave informed consent. which was signed before
randomization
. Patients were eligible for enrollment if
they met the following criteria: acute myocardial infarction
within the previous 6 to 50 Jays : =75 years of age ; either
10 ventricular premature depolarizationrh or '5 runs of
nonsustained ventricular tachycardia 13 to 10 beats, rare
a 1110 bcatsrmin) on a 24 h Holier recording with
a
Ig h of
interpretable ECG information
. A total of 502 patients were
randomized to receive one of four active drugs era matching
placebo . Dosing of study drug was performed in a double
.
blind fashion and involved three escalating doses or two
antiarrhythmic drugs for their respective placebos) until
a70r ventricular premature depolarization suppression was
observed (Fig. 11 . This study focuses on the 100 patients
randomized to receive placebo (Table 1)
.
The fedlot'in,v Null er
mrmdinga were obtained iii the l00
pa[fenrs rdgdonlizcd
ro rceive plocehur initial screening
[ape . dosing tapes during drug titration lone to sit tapes) as
well as mandatory 3, 6 . 9 and 12 month tapes. Placebo-
treated patients had between I and 12 Hotter recordings
mean A . 31 . The wide individual variation in recordings
was auributahle to a number o€ faclors
. primarily the num-
ber of dosing tapes. withdrawals and deaths .
Holier recordings to document gaidifying arrhythmia .
The majority of patients were entered into CAPS based on
an initial screening Holier recording, which was used as a
baseline for dosing ev iluation . However, if the first ereen-
ing Holier recording did not have a qualifying arrhythmia. a
second recording was permitted to identify additional qual-
ifying patients . When a second recording was required to
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qualitl the patient . which occurred in '_J plac,b o-rre .n1d
patients . a third Holler recording w :r, mandatory . ihlt rf
concern for data collection based on e\lreme ub,aniuom
'this third Holler recording was considered to he the ha,elmc
for dosing evaluation in those 24 paticnh .
Holler recordings were read locally . ssith qualm enntrol
performed by means of reference tape, : rd an csternal cole
laboratory . The results of these combined q .au to control
strategies led to >_9?Ci agreement in loge 5entriadwr prom
lure depolarization counts .
Stalisiical anal}:cis- Arrhythmia rule, are e'pres,cd h5
mean ± standard deviation and . i n time in,tnnce, . hs
median wtd interquartile tauge, Andt , cs sere pertrl lncd on
the log-transformed ventricular prem :aure depolarvattrn
eouut to reduce the influence of ellrente 0nInes and . most
i mportantly. t o approslmate the
:rssempiun of :utah,li of
variance of homogeneous normalh di,trihatcd 0Iriance
.
Because of deaths and withdrawal,, not ill patient, had i
Holler recording obtained :d all time paint, . Accordingly .
two sample 1
tests are used when all aoadahle date tic
considered (even though the sample , arc nol independent .
we assume that the test, wooed Iihtlo be cor,eroeosci mri
paired r tests {61cNemalA lost to, Inadcncc d
.wn whoa
anatsses ant rontrictcd to patient' with dnr.s usailahic :r
.dl
time points
. hourly sentriculOr n Ir Jepal . :nr.ltlon
variation was aese,sed ut screening both i, a dependent and
in independent s'a rlahle to assess whether it was relatcal to
ventricular premature depolarization 0o ration )set long
intervuts I I to 2 weeks and 3 months[. Heads , . n :rnon we,
calculated after adlustmcnt for diurnal o rriation hs e-
-nation
of the sentricrllur premature depoh,rieaion sari u n
during dayume 19 1st to 4
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34cekls cinauun sse' asses-ed Swot . I l compaT-
thc ,_r .-nine and first do,inc Holler recordings [mean
I m I I i - J dey,!, and '_) the 1 1 month follow-up and
C nu nl- w,,,houl rcardmg .
t ..rl,r
I,rut,,,~~ssrdruuLvIiIrrvrnlcl :logIVPD-h- II=
Ia
. o
.he1 (i is the amhienl seniricular premature
dcxlan'au.m VPDI rate fur paucm t . and S i, common to all
paacnn n Ire ungroLp of inicrc,t . We base published the
dal : .1,,I'hi .,prhpiesunl,lsIIY1 .
Results
I he itr.r n utlcuts randomitr•d to the CAPS placebo group
h,Id the screening Hnner recording performed an ascrage of
II :ecchtohatenterJCate myueard!al Infarction . An
,1001 rOe of n i Holler recordings were available fur
doer the I sear trial . Thrrl-ne patients in the
I. at', pl ;r<dFo Group dropped out during the trial because of
clinics one ma ideath fi. mwcardhil infaretmn II. presumed
vets if olds drlg tprnarrhythmin ill . worsening hear
allure '1 or other masons including noncompliance or
rib i ore , .n preference In = GI .
Selection and analysis of ennseeutire Halter recordings
I
Fable 2i
. Silty'-nine of the 11111 CAPS pkscho-trcaied pa-
lad - analyeable Holler recording at every study
In
:r,„I
'h-cline,
dosing and 1- fi . 1) and 1] monthsl .
yualy,h ofchanges in semrrcular premature depolarizalions
.tad Ucnut,ulal tachycaidia was performed with this com-
plctc cro,:a .aaddition to till
available Holler recording data
In- the entire placebo group . The clinicai characteristics of
the CAPS placebo-treated patient, are described in Table I .
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Figure !.
Distribution of senulcuPe: premature depulnnrationt
i VPPcl to ;hr hmu of lire haschn) . screening Halter recnrding,'1'he
few patients rrr h .1Its centrie.1Iar premrlurr denolariselinss'h ;rtr
patient, elipihI' an the ccconJ of Ian ;nlomp: a to stem a pal
itnt
. In
those cases
. a third Halter recordmp ual mandated by the ,mdr
prntncoI coo Methods)
in = 7N1 and 36 -
173 runs of ntmsustained ventricular
tachycardia'day !n = 33)
. The ventricular premature depolar-
ization disi~ihoiion among the 1110 placeho•trcaled patients at
the time of mndemization is graphically depicted in Figure 2 .
Reflecting clinical pasties
. the screening Holler recording
was used in CAPS as the comparative baseline study for
assessing drug effect
. although it *
;is likely to be hissed (the
study design mandated screening for an arrhythmia cutoff
point, as well as being obtained nn no placebo therapy) . In
contrast • the first dosing Holler recording from each patient
was less likely to represent an extreme observation and was
obtained during double-blind placebo-controlled conditions .
Some analyses of the first dosing or titration Holier record-
ing are included, considering it as the "unbiased baseline
study - in that it is already conditioned by the placebo effect .
The ventricular pr .matare depnlnri;nrioer disrrihatitat of
both .screening Holier rei'ordings and unbiased hrerelfnr
(first dnsingl Holier
reronhncs are reprrssemed in T !n?tt 2
.
where the apparent regression to the mchn value in the I
week interval separating these Iwu studies can he readily
observed (25) . Because 24 patients qualified only Pn a
second Holler recording (see methods) . a third Holler re-
cording become the reference Holler recording Pot dosing ;
consequently_ 17l of patients had < I h ventricular premature
depotarizationsfh on the baseline Holier recording . whereas
251f had <10 ventricular premature depolarizalioosih by the
time of the first dosing Holier recording iTahle
Natural history of ventricular arrhvthmias in the C4PS
placebo-teated patients. Figure 3 represents the ventricular
premature depolarization rates at selected study intervals for
100 placebo-treated patients with Holier recording data
avnilable at any time, Whether all patients arc analyzed as in
Figure 3 or data analysis lialilud to the 69 placebo-teated
patients with data at all time intervals . (here is a significant
tp - 0,004) reduction in arrhytlsmiu frequency between the
screening Holler recording and the unbiased baseline study .
This iv followed by an insignificant increase in ventricular
premature depularizations seen between the first dosing and
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Figure 3.
Arrhythmia fregaendcs for the phmeho group In = HO
throughout (hc year
. Net all patients x reprocessed at -.y
inters,) as a result of some patients withdrawing From the study .
Similar ] ..ad, am preie n if only the 119 patients with data al each
time
Point are represented . The mean valnc is displayed ns well as
interquartile interval Ihox) with the standard deviation (bars.
VPDs = ventricular premature depularizations .
the 3 month interval . After the 3 month intervnt . the fre-
quency of ventricular premature depolarizatiuns gradually
declined throughout the year. with a significant reduction
between 3 and 12 months (p = 0 .04).
The prevalence of non.c[rstnined ieotriealar raellyrarifin
in the entire pktcelx, group is presented of the idenrirnl fine
inrrrraIs in Fikurr, 4 . Although one-third of the placebo-
treated patients had one or more runs of nonsustained
ventricular tachvcardia at the time of the screening Holler
recording
. the prevalence of ventricular tachycardia de-
creased throughout the year to 13% in the placebo group by
12 months Ip a 11 .07 versus either screening or first dosing
Hailer recording). Withdrawals among the group of patients
with and without ventricular mchycardia m screening are
comparable and did not explain differences in the prevalence
of runs ol'ventricutar tachycardia over the I year interval- A
similar reduction in the percent of patients with couplets was
noted, decceasteg hum bl S at baseline to 54% at 12 months
Ip = 11 .021 .
Figure 4. Percent of patients menifesuiag runs
of nonsusmined
ventriculur rlchycunlia lO'fl at curious intervals of placebo admin-
i,lr:dlanf3 to Wheat, at a it, of 0 1110 benls'minl .
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Influc .tce of ventricular arrhythmia lariabilih on clinical
perception (Tables 3 and J) . The CAPS eras do,Igncd to
simulate one approach in clinical produce
. iumrIt
nc
lastin-
furctioee patients with ventricular premature depnlari,anon, .
then finding the lowest dose of a drug to sutcly eupprcs . t-e
ventricular premature depolarizalions IFeg . II The fre-
quency of ventricular premature d .pale'iza .ion, noted re
sequential Holler recordings obtained in indiudual patient,
varied greatly
. such that many placebo-treated patient,
appeared to achieve the CAPS criterion of
_'ll',' r onto . ;'!ur
premature depolanruion suppression during dosing . Placc-
bo-treated patients duvcluping' upparcm
,c111,I,u1 .11 pccro. .-
tore depolarization suppression al s,nou, 3o,ing mlcruit,
are listed in Table i rite individual data hcwona the etc .u
dosing cannot he properly estimaicd la,-- ilk :ud~
design (Fig. I) eliminated patiens if they did nut
respond to any dose of tether of ]hc two drug, rnndomh
selected tin this case placebo I and 'Ii
slier¢,, addoirnal
patients dropped out or died
. All camp .,isussare muse ,sith
reference to the bass ac e
-,
Ho ',iu ruse din:o
actually used by the phs'lciun in e,ch p
:nieni tar seheyucnl
dose titration For Insttince h the end it duisina 4', dl' . ' . 11
of
9h placebo-treated patients reaches
: I've snppru„ioncvtairn
(Table 3) . In a similar format
. Tabled depicts the placenn'
treated patients who d eveloped. a n ;ipparent proarr a
.hmi
response ." Consistent with 'Table 1- all urn ittlunin de1,l ale
compared with the baseline Hotter roc .rrdmg :x', of patient,
Table i. Apparent "Pr,u-rhs
Iii i e Ede t" 1.,. Plsep„
\ u al 11n„m r. C .,. ,v., Do, na im- , ,,
stas,m
.,1
Oh-, ed S Pie
Inc '%I
Iva-tut
nn-ally
5m-I nlsi
1 .11111-_ .IXm
dept
Pull
PRxrt Et :AL
ll'rIt^ ,8•I rut, hl '.5 „F'F'- ely L i sa 'aRHS IH41Al
rod
o sro
® `NOR-
.1Vr
assutra
oa.m g
, n , r,,,,„ r:,.m ,1 „ Ficurr5 . tndl .iJudAvivline'andlabilosofearsoreonsustains
,eataiular Luhtcardiu 1);F) curio¢ the :dal . Although oit, tI
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. It additional parienrs developed rca
,r Lr, hpcerrlia at the time inlznals dep,cad . Differences in
	 e
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hurlnlntalcolumnsorsaresultnt are pat
-
eonwirlvtrawine
in m the •cede .
had d In -fold increase in ventricular prelral . :-e depolariza-
tion, hr the end of dosing.
Fluctuations in runs of ventricular larhycardia on placebo .
1 sr.u,d dcmonsiration of the tremendous cariahilits oh-
--d in run, of nonsusiained ventricular taehccardie is
pro cried it, Figure S-Although only 13 pauems initially had
„ustainCd ventricular iacheeardia
. 73 addl+innal patients
i sdoned nonawiuined ventricular tachvcardia al leas)
on, c Jut me the mter,air sho ,in in Fio_ure 5
. an observation
h i t coins hi misinlerpretcdasa 'prearrhsthmic response. °
Iikecu,c 'fl of the ii pla :cbp-trealeu patients initially
mandc •I nm sroulcuhrr lach,cardla had 'local ventricular
mch, ;,,rd, ., euppre,aau during nt least one of the study
Inlcn .J, of primary importance_ Figure
5
depicts the ex-
iraorJtn.xr', fluctuations in the presence or absence of runs of
yemncul .Inuch}cardiac adoidual palacnlsoverthe I year
,turfs mlcr,al
. In must palienlc ebhihitine spontaneous
oppcaranee or disappearance of nonsusiained ventricular
lachrcacdia- there were only one or two runs daily, with
none hloinc more than five rum of nonarstained ventricular
1a:9Seardia . The likelihood of detecting nnnaustained yen
rr, .~rt .rr u.. hacartli : : is related to :he frequency of Holier
recording rumpling
. Figure 6 depicts a range of ventricular
€echcarrdia prevalence rates that could be reported in this
group of patients Ibctween 11`f and nearly 90%1 depending
on the number of Holier recordings performed
.
Clinical Parlors potentially aiec0ngarrhythmia variability .
Af a hlptc factors were examined to gee If the initial frequency
, I'tcntrralar premature depolaeizations or subsequent , an -
afoltty w .,s ;lfl'ecied by towline characlenslics . Age . gender
.
hi,ton of congestive heart failure
. coronary risk factors. left
ventricular ejection fraction and concomitant medications .
all hall no relation to baseline venlricutar premature depo-
larization range or predicted varahility
. The presence of one
AJf
more runs of nonsustained Ventricular lachycardia at
baseline study was associated with higher ventricular rates
premature depolarization at baseline
In -= 0
.04). Venlric-
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Figure 6 .
The influence of the frequency of performing Holier
recordings on the detection of runs of
non-tanned
ventricular
tnehyeurdla iVTJ in individual placshotreated patients in the Car-
diac Arrhythmia Pilot Study ICAPSI .
War premature depularizatius variability was not related to
ti,e initial (sct'ecning( frequency divided in tertilesl nor did
initial hourly
variability
have any relation to subsequent
variability at any time interval . Attempts to find a positive
relation between hurt- (for example, weekly( and long-term
ventricular premature depolarization variability all failed to
reveal any significant association .
Discussion
The 100 patients followed up for I year in the placebo
group of the Cardiac Arrhythmia Pilot Study ICAPS I pro-
vides the most comprehensive . long-term objective analysis
of ventricular arrhythmias after myocardial infarction re-
ported to date . The unique aspect of this study is that
previous reports of arrhythmia variability were made on
statistical estimates of variability based on a few days of
Halter recording observations in a variety of study patients
.
whereas this study observed the actual long-term ventricular
arrhythmia variability in a group of patients at increased risk
of sudden death .
Selected aspects of CAPS design
. In CAPS . eligibility
required a recent myocardial infarction and ?IV ventricular
premature depolarizationslh or asS runs on nonsustained
ventricular Inchycardia on a Halter recording . targeting a
clinically important group of patients at increased risk of
sudden death 13 .41 . The objectivity of the arrhythmia data is
strengthened in that they were obtained under placebo .
contru :;ed double-blind circumstances. Furthermore. by vir-
tue of the progressive dosing sequence (Fig . 1), the study
design simulates clinical practice, so that the data presented
have direct clinical applicability. The importance of a paral-
lel placebo group in assessing the risk-benefit ratio of an
antiarrhythmic drug is highlighted by the fact that significant
clinical events (death, pruarrhythmia or heart failure) oc
earned in 19th/ of placebo-treated patients, which could easily
be assumed to be . directly or indirectly- a consequence of
antiarrhythmic therapy .
Multiple biases introduced by aspects of this study design
may confound the attempt to describe the natural history of
postinfarction ventricular arrhyrhmias in this group of pa-
tients . In CAPS, patients were entered aver a moderate time
interval . the number of dosing Halter recordings varied
(until suppression was observedi and subsequent recordings
between 3 and 12 months were not obtained in all patients (as
a result of death, withdrawal or other factorsi . Figure 6
demonstrates the significant bias introduced in renaming ihe
incidence of runs of ventricular tachycardia when Halter
recording sampling frequency increased . As the number of
Holier recordings increased . the percent of patients with at
least one run of ventricular tachycardia also increased,
approaching an incidence of loo% when >I0 Holier recard-
ings were performed . In the present study, nonsustaincd
ventricular tachycardia was a low density event. almost
always occurring as -5 runsfday (Table 2)
.
Long-term fluctuations of ventricular premature depolar-
tralions on placebo . In groups of patients SUM-18 acute
myocardial infarction, increases in ventricular premature
depolnrizations after hospital discharge have been reported
(g-131. In contrast
. we observed a highly significant reduc-
tion in ventricular premature depolarizations initially, when
the baseline screening Holier recording was compared with
the first dosing Holler recording lunbiused baseline) . This
has not been previously reported and may be explained by
the selection of a unique eligibility criterion reflecting an
en Creme group of ar, h or nia frequencies ; thus, the observed
arrhythmia reduction may represent either the placebo effect
r,r regression to the mean (25)
.
However, we then observed
a 1 .5- to 2.5-fold increase in ventricular premature depolar-
ization frequency range between I and 3 months, although
this did not reach statistical significance . The increase in
ventricular premature depolurizations observed during this
time interval is consistent with other studies, In the Beta-
Blacker Heart .Attack Trial (SHAT) (13), there was a 30%
increase in complex ventricular arrhythmins in placebo-
treated patients at 6 weeks as compared with a predischarge
holter recording .
Of more relevance to clinical practice are the observa-
tions of individual decreases in ventricular premature depo-
larirations (apparent
suppression)
or increases (apparent
proarrhythmia) that were noted in the placebo group. Clini.
cians must use criminal when inferring that observed sup-
pression is the result of an antian -
hythntic drug effect in
individual patients like those in the present study . A single
Halter evaluation of antiarrhythmic drug effect (Table 31
yields a 27% "apparent
efficacy''
rate, whereas up to sin
separate [loiter evalualions of antiarrhythmic drug effect
yields a 48% apparent efficacy rate, when the suppression
goal is a 70°% reduction in ventricular premature depclariza-
tions and one 24 h baseline Halter recording serves as the
comparison (Table 3) . A dramatic reduction Iin ventricular
premature depolarization in individual patients on placebo
over 1 to 2 year intervals simulating long-term drug efficacy
has been documented previously in a small study (26) of a
group of patients with ventricular premature depotarizations
with a lower risk than seen in CAPS study patients .
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Confidence that a real antiarrhythmic drug suppression
effect is demonstrated is increased as greater suppression of
ventricular premature depolarizations is achicvcd Our cz.,m-
pie . 907 suppression goal) . which could reduce the place
hot response" or misinterpretation rare observed in this trial
by approximately 5017 (Table 1) . Another practical lesson
from these placebo data is that the chance of inferring drug
suppression increases as more frequent Holier recording,
are obtained during antiarrhythmic drug therapy . Prosious
studies (17-201 estimated that obtaining multiple baseline
(pretreatment) Halter recordings could provide an ultern,,-
live solution to adequately describe and interpret an indicid
ual patient's ventricular premature depolartoation -,anahd.
fly . but this approach is usually impractical in clinical
practice given the expense involved and limitations in reim-
bursement allowed .
Frequency of proarrhythmia on placebo therapy. Gcen
the known risk of proarrhythmia when using antiarrhythmic
drugs . observations of "natural" fluctuations in ccntncular
premature depolarizations are useful when attributing :Ir-
rhythmia increases to a toxic drug effect . Based on out
placebo group data, ventricular premature depolarizati : n
increases >?,0009c are imusual compared with n bane ire
value . This is consistent with our previous report t'm that
used statistical estimates to calculate Ihlat n 1
.780'
; mcre.I,c
in ventricular premature depolarization wit, nece„ar, m
establish a "proarrhythmic response" with 95 1 1 confidence
intervals in patients with ventricular arrhythmme, aflcr acute
myocardial infarction . The present trial pru,idc, Ilctu ;d
long-term data to confirm these precious estimate, .
The CAPS definition of proarrhythmia mitered i ,lidmf;
scale based on the initial baseline arrhythmia Ircqucncy
(6.27) . However, it is apparent from these data that a to-laid
increase in ventricular premature depolarization, hosed ~ a
single Holier recording evaluation o 0-fold inereu,u in
ventricular premature depolarization if up to sic Helicr
recording evaluations are performed i, necessary to impli .
cate a true prnarrhythmic drug effect in the ahsence of other
supporting data . This is an important issue when interpreting
the proarrhythmic rare of an iucesticatnnal ;ouch ihi thnuc
drug utilizing the pharmaceutical data bases . In clinical
practice, even if the ob,crced iecrcese in ccntricuhu prcma .
lure depolarizations is a variability effect . a new drug would
probably be selected because the treatment goal is arrhyth-
min suppression .
Nonsustained ventricular lathscardia as a priman sup-
pression end point The ectreme cariahlhlr of run, of can-
trteutar taehycardia documented in It, present lad1 is
related to the small number of 1,,I% ran, of centric ear
tachycardia in individual patient, Only onethud of the lot)
placeho-treated patients had runs of ccntricular tachycudia
at baseline study . 01 these 33 patient,. only 7 had sic or
more runs of ventricular I ichccardiaduc I table 'I The tact
that runs of , cnlricutar u,chycardia arc not abundant end
their presence lahil,, diminishes the degree to which 'een-
tricolar tachycardia suppression" could be considered elin-
mm_r e tnei.d as a primary end point of therapy to a po,un
.
lacuna population . In other patient groups ire
which runs of
non,u .t:uncJ venlrtctiter tachycardia era more precalem . a
,itrprt, .t r foal foe used on nonsustained , or rlculartachc-
cerdcl I, ,11ll practical_
Published data 1191 on the vuriahiliu, of runs of nonsus .
coned cc ii icuiallaehycardia suggest that ill, palieets rn,m-
Ife,uec Ice„ than five runs of nvnsuslained cc ttricular )ache.
cardl,lda :. must have ''complete suppression" to infer a
drug ertca . In that placeho group. the low uen,ny of tuns of
c entneul .t c Inchvecrdia makesv .•n
tricidur tachycardia ah-
alitian'' i, the primary suppression coal of therapy an
mtcrprciatne mghlmarc
. Potential mlsdasthcanom of eI-
Ihe- - ippic„ion of ventricular tachycardia or development
of ncc +cntricular tachycardia during therapy are the rule
rather than the exception, as graphical)c illustrated in Figure
It Ic- than total oppression of scotricular tachycardia
:e,uln tram therapy. n o inference about a drug effect is
fo„Ihlc Thus. abolition of nonsustained ventr .cular tachy-
cardc, n necessary hut by itself not sufficient to establish a
den_ c1Tec1 in this group of patients . The spontaneous
ctis .Ippcanince of ventricular tachycardia is consistent with
clbserc :u,ons made in a precious placebo-controlled .single-
blind ,md, 1281 of n more heterogeneous group of patients
ccuh cntricular tachycardia. This trial also emphasizes the
legs-: Io cchich the reported incidence of nonsustained
scntricuiar tachycardia is dependent on Holier recording
sampling Irequeney Ibig. 61 .
lnahsis of sources of arrhsthmia cariabililr . The inabil-
ity to atcnof v significant sources of the observed ventricular
tailor dcpululizatiou intiatdlity shat is . ptcdicrisc,t•' -
.ct •I wa •. .tisappointing. Logically . those patients manifest-
. .u'c . burly .cntricular preumtme dcpularitatiun %art-
zbd -n,c a cater diurnal arrhsthmia P.uemations might he
c,perted to manifest greater long-term changes . L'nfortu-
nucly we were unable to establsh any risk factors to allow
c . In 1lentils prospectlvtlc patients c,i(h the greater long .
farm c!inahility . The inability to identify factors associated
curb gi .uer cemricu1a, premature depolarization variability
amsnteni ooh precious published investigations 119 .201.
with the possible exception of the patient subset taking a
ti,-IU-udrcncrgie blocking agent that manifested greater yen,
tricolor premature depolarization variability in one study
(2th. However . the sample sizes of the past and present
,mdlc, in the selling of a signihcam natural variation may
lack power to detect moderate differences
.
Conclusions
. A number of practical conclusions used on
ihl, d.a ., include the following . I) Although a baseline 24 h
Holier recording is useful for assessing sudden death risk . it
has crmu , inadequacies for use as a comparative baseline
study from which to assess ventricular arrhy'thtnia suppres-
,ion in a patient . 2) Alternatives for improved accuracy of
., essnrent of suppression include either monitoring for
longer baseline intervals or increasing the target percent
,upnres,ion goal . 31 Frequent Hotter recordings obtained
dorm, :mnarrhythmic drug administration dramatically in-
R	
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crease the opparamity to sample arrhythmia frequency
during "am estremc lime period, •
inn easing the chances far
mixclassihcatian fit IIIhIII CI'pl'Clab'.m . H1 (ijv rn ties ken dam
siiv and great a,rinhililc of run, of ventricular Iachscardiee in
this group of patients . - venlriculnr tachvcardie huppress
sion •' as the primary and only end point of therapy is
impractiad and the results are haiurde,us to interpret
Till, studrL dad nut ad i d,, • ,;tut . r,/ aiuahrr
.nrppresxi,tn gl rrnii,idor nrrhrlhmiar ate joeifgli+rchint
parirwtr n -
ill aslant
(Grin
hiliity 4JIP, A full-scale venlric •
ular premature depolori,vuion suppression trial ICAS'lI in a
similar croup of patients i, currently in progress and interim
results have been published if i. Neither the CAST (It our
previous trials Cv1 hosts offered ,nv optimism that venh ;"-
Flar arrhvthnfia supprtssian in pestinfarction patients is
hencffciol . Suppression end points for sponLincous ventric-
ular arrhylhmlus have thus far heen ,trhirr,trily chosen and of
no proven benclit L 3f)1. The dmdysis of the placehn-treated
patients tram LAYS prtn'ide, or iddiliunul mate of caution
regarding the tcstinL of the suppression hypothesis because
the documentation of arrhythmia suppression is a complex
6,IIe .
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